Navigation Links
The World Economic Forum Announces Technology Pioneers 2008: Mondobiotech Selected
Date:11/30/2007

BASEL, Switzerland, November 30 /PRNewswire/ -- The World Economic Forum today announced 39 visionary companies selected as Technology Pioneers 2008. Mondobiotech has been selected as one of these Technology Pioneers. The Technology Pioneers 2008 were nominated by the world's leading technology experts, including venture capitalists, technology companies, academics and media. The final selection from 273 nominees was made by a panel of leading technology experts appointed by the World Economic Forum. Technology Pioneers 2008 are invited to participate in the World Economic Forum Annual Meeting 2008 that will be held in Davos, Switzerland, from 23-27 January and in the Annual Meeting of the New Champions that will be held in Tianjin, People's Republic of China from 25-27 September 2008.

One of this year's Technology Pioneers is Mondobiotech, an independent, research engine biotech company focused on the development of treatment options for fatal and neglected rare diseases. It successfully develops human peptides to treat patients affected by rare diseases. This is done through its "search and development - S&D" method, access the global scientific know-how on potential therapeutics.

"This World Economic Forum Selection as a Technology Pioneer 2008 is an incredible honour for Mondobiotech and a validation of our unique business model," said Fabio Cavalli, CEO of Mondobiotech.

"As this is the first year a Swiss biotech receives this prestigious award, we are especially pleased to be granted this international recognition. This prize clearly supports our mission to change the world in healthcare and find the cure for an increasing number of the 7,000 neglected diseases in the near future."

Technology Pioneers are companies that have been identified as developing and applying highly transformational and innovative technologies in the areas of energy, biotechnology and health, and information technology. To be selected as a Technology P
'/>"/>

SOURCE Mondobiotech AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
3. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
4. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
5. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
6. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
7. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
8. PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso
9. Doping technique brings nanomechanical devices into the semiconductor world
10. Advanced Instruments Introduces Worlds Fastest High Throughput Freezing Point Osmometer
11. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 3Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 4Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 5Genmab Discloses Target and Development Plans for HuMax-Inflam 2Genmab Discloses Target and Development Plans for HuMax-Inflam 3New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 2New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 3New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 4